Replies to post #108219 on Avid Bioservices Inc (CDMO)

[freethemice]

The references to bavituximab are all about HCV and the trial done with bavituximab.
Nothing new there. It is a review paper.

[BioBS2012]

Back to the science of Bavituximab

I thought this paragrapgh was quite illuminating....

"Targeting PS on cells infected with multiple different viruses and on virions
themselves is a promising antiviral strategy. Although resistance has developed in
monotherapy trials with ibalizumab (an anti-CD4 antibody), host-derived antigen,
such as anionic phospholipids, on virus-infected cells are independent of the viral
genome and as a consequence the acquisition of drug resistance should be
theoretically less problematic than with agents that target virus-encoded
components."

[sunstar]

djohn, the first reference is bavi for HCV. These researchers suggest, as others have, running a longer term trial of bavi and Ribavirin as a tag team to replace troublesome interferon therapy. There’s a lot of future waiting in bavituximab for treating viruses. Good stuff!

We lead with cancer, treating several indications paired with a variety of chemotherapies as well as radiation.

Bavi is a team player!

IMO

sunstar